GLP1R and obesity disorder: The support of endocrinologists specialized in the management of pharmacological treatment of obesity should be requested, as emerging evidence shows the benefits of glucagon-like peptide-1 receptor agonist for managing insulin resistance associated with polycystic ovary syndrome.